サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1446825

ペンニードルの世界市場：2024～2031年

Global Pen Needles Market - 2024-2031
出版日: | 発行: DataM Intelligence | ページ情報: 英文 206 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ペンニードルの世界市場：2024～2031年
出版日: 2024年02月13日
発行: DataM Intelligence
ページ情報: 英文 206 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界のペンニードルの市場規模は、2023年に35億米ドルに達し、2024～2031年の予測期間中にCAGR 11.8％で成長し、2031年には85億米ドルに達すると予測されています。

世界のペンニードル市場は、インスリン製剤が一般的に使用される糖尿病患者の増加に伴い、需要の高まりを示しました。メーカーは、極細針、強化された安全機構、改善された注射技術など、様々な革新的な機能を導入しています。

ペンニードルは、患者がヘルスケア専門家を必要とせずにインスリン投与を行うための便利な方法を提供します。糖尿病のセルフケアと自己管理の動向の増加は、ペンニードルの需要の増加につながった。ペンニードルは、その進歩により利便性と安全性が向上し、患者がより快適に使用できるようになった。

北米は世界のペンニードル市場で成長している地域の一つであり、医療施設の増加や医療技術の高い導入により、市場の大部分を占めています。同地域では糖尿病患者が増加しており、人口の増加が市場の需要を牽引しています。これらの地域の政府は、ペンニードル市場が提供する進歩についての意識を作成するために様々なイニシアチブを適応させます。

技術の継続的な成長は、ペンニードル市場で示しています。アジア太平洋は最も高い成長を示し、人口は他の地域と比較して比較的高いです。中国、日本、インドでは、ペンニードルの消費が増加し、大きな成長を示しました。例えば、2022年9月9日、医療業界の世界的リーダーであるTerumo Indiaは、インシュリン注射を必要とする患者のためのFineGlideの発売を発表しました。

ダイナミクス

慢性疾患の増加

糖尿病、心血管疾患、がんなどの慢性疾患が大幅に増加しています。したがって、ペンニードル市場の需要が増加しています。このような疾患では定期的な薬剤投与が必要であり、現在ではペン型注射器を使用するのが一般的です。ペン型注射器は、適用が容易であり、外部からの支援なしに患者が直接投与できる可能性があるという現実から、注射可能なドラッグデリバリー構造の規範として出現しました。

例えば、2018年11月14日、HMDは糖尿病患者のためのDispovanペン針インスリンを発売し、インドは糖尿病患者に苦しむ7,400万人を示しました。Hindustan syringes and medical devicesは使い捨て注射器の大手メーカーであり、Dispovanインスリン針を発売し、この進歩はペンニードル市場の成長を後押しすると思われます。

糖尿病は、血糖値を維持するために定期的なインスリン投与が必要です。スマートインスリンペンは、投与量の追跡、リマインダー、スマートフォンアプリとの接続などの機能を提供し、個人がインスリンレジメンを追跡するのに役立ちます。服薬アドヒアランスを促進することで、スマートインスリンペンはより良い疾病管理と健康アウトカムの改善に貢献します。

例えば、2023年3月14日、スマートインスリンペンは再使用可能な注射器で、糖尿病患者が病状をより簡単に管理できるようにします。このペンはスマートフォンのアプリと連動し、血糖値、インスリン投与量、食事の量を計算するプロセスを簡素化します。糖尿病管理に関わる計算を自動化することで、スマートインスリンペンは、糖尿病の症状を経験する個人が直面する課題のいくつかを軽減します。

ドラッグデリバリーの代替手段への嗜好

消費者の中には、注射針に対する恐怖心や嫌悪感から、ドラッグデリバリーの代替方法を求める人もいます。これには、インスリンポンプ、吸入器、経口薬などの技術が含まれます。このような代替手段の利用可能性は、特に針を使わない投与を優先する人々の間で、ペンニードルの需要に影響を与える可能性があります。

ドラッグデリバリー技術の継続的な進歩は、インスリン投与のための、より便利で新しい選択肢を導入するかもしれないです。例えば、研究者はマイクロニードルパッチ、埋め込み型デバイス、吸入型インスリン製剤の使用を模索しています。代替技術はより使いやすく、効率的であることが証明されており、これらは市場の成長を後押しすると思われます。

ペンニードルは、インスリンポンプのような代替ドラッグデリバリーデバイスよりも一般的に手頃な価格であるが、糖尿病管理の全体的なコストは依然として個人にとって重要な要因となり得る。保険の適用範囲や経済状況などの要因により、患者の中には、コスト削減や長期的により価値のある代替方法を選ぶ人もいます。

例えば、調査チームは3つのペプチドを含む植物性インスリン制御システムを発見しました。植物性インスリンでは、材料が微生物に分解される前に、植物細胞は酸からインスリンを保護します。研究者は、インスリン様化合物として使用される植物ベースのタンパク質を生産する植物を遺伝子工学的に設計するなど、様々な面でこれらの植物ベースのインスリンを探索しました。

インスリン投与におけるペンニードルの限界

ペンニードルは、4mm～8mmまでの様々な長さとサイズで利用可能です。適切な針の長さは、体格、皮下脂肪の厚さ、個人の好みなどの要因によって異なります。しかし、皮下脂肪が厚い個人は、インスリンが望ましい組織の深さに到達しない可能性があるため、短い針の長さで効果的にインスリンを注入することは困難であるかもしれません。

脂肪過栄養を避け、安定したインスリン吸収を確保するためには、注射部位をローテーションすることが不可欠です。しかし、同じ注射部位を繰り返し使用すると、瘢痕組織が形成され、インスリンの吸収が一定しなくなる可能性があります。個人によっては、使用できる部位が限られているため、注射部位を一貫してローテーションすることが困難な場合もあります。

ペンニードルは正確な投与量を提供しますが、投与量測定におけるヒューマンエラーは依然として起こり得ます。注射をする前に、投与量の指示に注意深く従い、投与量を再確認することが重要です。誤った取り扱いや誤った測定は、投与量の過不足につながり、血糖コントロールに影響を与える可能性があります。

使用済みの注射針を安全に廃棄することは、偶発的な針刺し損傷や汚染を防ぐために重要です。適切な廃棄方法は、特に旅行中や公共の場では、必ずしも容易に利用できるとは限りません。個人と地域社会の安全を確保するためには、責任ある廃棄方法が必要です。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 慢性疾患の増加
      • 代替ドラッグデリバリーへの志向
    • 抑制要因
      • インスリン投与におけるペンニードルの限界
    • 機会
    • 影響分析

第5章 業界分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 製品別

  • 標準ペンニードル
  • 安全ペンニードル

第8章 長さ別

  • 4 mm
  • 5 mm
  • 6 mm
  • 8 mm
  • 10 mm
  • 12 mm

第9章 治療法別

  • インスリン療法
  • グルカゴン様ペプチド-1
  • 成長ホルモン療法
  • その他の治療法

第10章 エンドユーザー別

  • 病院
  • 診断センター
  • 外来手術センター
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • ロシア
    • その他の欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他のアジア太平洋
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Becton, Dickinson and Company
  • Novo Nordisk A/S
  • B. Braun Melsungen AG
  • Owen Mumford
  • Terumo Corporation
  • Nipro Corporation
  • Allison Medical
  • AdvaCare Pharma
  • Berpu Medical Technology
  • Trividia Health

第14章 付録

目次
Product Code: MD1625

Overview

Global Pen Needles Market reached US$ 3.5 billion in 2023 and is expected to reach US$ 8.5 billion by 2031, growing with a CAGR of 11.8% during the forecast period 2024-2031.

The global pen needles market witnessed rise in demand as an increasing number of diabetes patients in which insulins are commonly used. Manufacturers introduce various innovative features such as ultra-thin needles, enhanced safety mechanisms and improved injection techniques.

Pen needles offer a convenient way for patients to administer their insulin doses without the need for any healthcare professionals. The increase in the trend towards self-care and self-management of diabetes has led to an increase demand for pen needles. The advancements improved the convenience and safety of using pen needles, which makes them more comfortable to use by patients.

North America is among the growing regions in the global pen needles market and covers a large area of the market due to its rise in medical facilities and high adoption of medical technologies. The region has witnessed increasing diabetes patients and a growing population drives the demand for the market. Government in these region adapts various initiatives to create awareness about the advancement that pen needles market offers.

Continuous growth in technology is witnessed in the pen needles market. Asia-Pacific witnessed the highest growth and the population is comparatively high compared to other regions. China, Japan and India witnessed major growth, as consumption of pen needles increased in these countries. For instance, on, 9 Sept 2022, Terumo India a global leader in the medical industry announced the launch of FineGlide for patients who requires insuline injections.

Dynamics

Growing Prevalence of Chronic Diseases

Chronic diseases such as diabetes, cardiovascular disease and cancer significantly increased. Thus increasing demand of pen needle market. The diseases require regular administration of drugs, which is now typically done using pen injectors. Pen injectors have emerged as the norm for injectable drug delivery structures because of the reality that they are easy to apply and may be administered directly by the affected person without any external assistance.

For instance, on 14 Nov 2018, HMD launches Dispovan pen needle insulin for diabetic patients, India witnessed 74 million people suffering from diabetics. Hindustan syringes and medical devices is a leading manufacture of disposable syringes and launched its dispovan insulin needles this advancement will boost the growth of pen needles market.

Diabetes requires regular insulin administration to maintain blood sugar levels. . Smart insulin pens offer features such as dose tracking, reminders and connectivity to smartphone apps, which help individuals stay on track with their insulin regimen. By promoting medication adherence, smart insulin pens contribute to better disease management and improved health outcomes.

For instance, 14 March 2023, on Smart insulin pens are reusable injector pens that help individuals with diabetes manage their condition more easily. The pens work alongside a smartphone app, which simplifies the process of calculating blood sugar levels, insulin dosage and meal sizes. By automating the maths involved in diabetes management, smart insulin pens alleviate some of the challenges faced by individuals experiencing diabetes symptoms.

Preference for Alternative Modes of Drug Delivery

Some consumers have a fear or aversion to needles that leads them to seek alternative methods of drug delivery. It can include technologies such as insulin pumps, inhalers or oral medications. The availability of these alternative options can impact the demand for pen needles, particularly among individuals who prioritize needle-free administration.

Ongoing advancements in drug delivery technologies may introduce new and more convenient options for insulin administration. For example, researchers are exploring the use of microneedle patches, implantable devices and inhalable insulin formulations. The alternative technologies prove to be more user-friendly, efficient these will boost the growth of the market.

Pen needles are generally more affordable than alternative drug delivery devices like insulin pumps, the overall cost of diabetes management can still be a significant factor for individuals. Factors such as insurance coverage and financial situations, some patients go for alternative methods that offer cost savings or better long-term value.

For instance, Researchers found a plant-based insulin-regulated system that contains three peptides. In plant-based insulin, plant cell protect insulines from acids before materials brokes into microbes. Researchers explored these plant based insuline in various aspects such genetically enegineering plants that produce plant-based protein used as insulin-like compound.

Limitations of Pen Needles in Insulin Administration

Pen needles are available in different lengths and sizes, in which ranging starts from 4mm to 8mm. The appropriate needle length depends on factors such as body size, subcutaneous fat thickness and individual preferences. However, individuals with thicker subcutaneous fat may find it challenging to effectively inject insulin with shorter needle lengths, as the insulin may not reach the desired tissue depth.

It is essential to rotate injection sites to avoid lipohypertrophy and ensure consistent insulin absorption. However, using the same injection sites repeatedly can lead to scar tissue formation and inconsistent insulin absorption. Some individuals may find it difficult to consistently rotate injection sites due to limited areas available.

Pen needles provide accurate dose delivery, but human error in dose measurement can still occur. It is crucial for individuals to carefully follow instructions for dosing and to double-check the dosage before injection. Mishandling or incorrect measurement can lead to over- or under-dosing, potentially impacting blood sugar control.

Disposing of used pen needles safely is important to prevent accidental needlestick injuries and contamination. Proper disposal options may not always be readily available, particularly when traveling or in public settings. It requires responsible disposal practices to ensure the safety of individuals and the community.

Segment Analysis

The global pen needles market is segmented based on product, length, therapy, end-user and region.

Rising Safety Pen Needles Demand for Reducing Risk Factors

Safety pen needles are specifically designed to reduce the risk of NSIs and protect both patients and healthcare professionals. The rising number of individuals diagnosed with diabetes has significantly increased the demand for insulin administration devices. As more individuals require insulin therapy, the need for safe and effective needle options becomes critical.

For instance, 27 Jun 2023, Tracey sainsbury discuss that how diabetes is increasing, In 2010 EU directives introduced safety pens. Safety pen needles in insulin administration is crucial for patient safety and the prevention of needlestick injuries. Safety pen needles come in two types: active and passive. Active safety devices show the needle throughout the injection process, requiring the user to manually activate the safety mechanism. Passive safety devices cover the needle before and after the injection, but it may obstruct the visibility of the needle.

Impact of Pen Needles in Hospital

The compact and portable design of pen needles makes them suitable for use in hospitals where mobility and space are often limited. The simplicity of pen needle usage allows for quick and accurate insulin administration, which ensures effective diabetes management for patients. The factors lead to an increase in the growth of needle markets from the hospital sector.

The prevalence of diabetes among patients who were hospitalized witnessed 12% to 26%. A study found that around 2000 patients were diagnosed with hyperglycemia at the time of hospital admission. As insulin pens are cost-effective when compared to traditional injections, so this factor makes them the preferred choice for hospitals.

Geographical Penetration

North American Manages Diabetes with Pen Needle Market

The North American pen needles market has witnessed significant growth because the rise in diabetic patients created an alarming situation in the nation, a report by national diabetes statistics that the diabetes case rise up to 37.3 million. The region has carbonated drinks and foods that have high sugar consumption these factors increase diabetes which leads to an increase in the pen needles market.

For instance, on 28 Dec 2022, research conducted by JAMA open network finds that consumers with diabetes are still experiencing increments in blood sugar levels. For managing insulin therapy patients are commonly using insulin pens that provide more convenient options compared to syringes. Pen needles ensure safety and minimize the risk of infections.

Rapid Growth of Pen Needles Due to Increasing Population

Asia-Pacific has a major growth rate in the consumption of pen needles market. Countries like China, Japan and India witnessed increases in demand due to urbanization and growing population leading to increasing consumption of pen needles in these countries. The region heavily invested in healthcare infrastructure, including medical facilities and services. The enhances the availability and distribution of pen needles that, includes hospitals, clinics and pharmacies.

For instance, on 10 Jul 2023, According to the international diabetes federation the adult population witnessed 10.5% of people having diabetes, due to their living conditions. Around 42.5% of people suffer from diabetes in Delhi and every third person in the house, these factors increase the use of pen needle insulins as they are easy to handle.

COVID-19 Impact Analysis

The pandemic highlighted the importance of chronic health conditions, including diabetes. As individuals with diabetes are considered at higher risk for COVID-19 infection, there has been a growing emphasis on effective diabetes management, including insulin administration using pen needles.

The government-imposed lockdowns and restrictions on the movement and minimized hospitals because of their chance to affected by infection, many individuals have transitioned to home-based care. The shift has led to an increased demand for pen needles, as they are easy to use at home and allow for self-administration of insulin.

The pandemic has disrupted global supply chains, that affect the production and distribution of medical devices, including pen needles. Manufacturers have faced challenges in sourcing raw materials and maintaining production levels that lead to temporary shortages in some regions. The factors affect the growth of the pen needles market.

During a pandemic, there has been an increased focus on infection control and needlestick injuries. The has led to a higher demand for safety pen needles, which incorporate safety mechanisms to reduce the risk of accidental needlestick injuries and enhance patient and healthcare provider safety.

Scope

By Product

  • Standard Pen Needles
  • Safety Pen Needles

By Length

  • 4 mm
  • 5 mm
  • 6 mm
  • 8 mm
  • 10 mm
  • 12 mm

By Therapy

  • Insulin Therapy
  • Glucagon-Like Peptide-1
  • Growth Hormone Therapy
  • Other Therapies

By End-User

  • Hospitals
  • Diagnostic Centers
  • Ambulatory Surgery Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Russia
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • On 9 May 2022, Roche Diabetes launches ACCU-Fine pen needles for painless delivery of insulin, which includes a 33G 4mm variant. It have main three key features that ensure comfort to consumer and easy to use.
  • On 25 May 2022, Owen Mumford announces that the safety pen needle will join unifine safe control brand. The provides safety and control and also protects from needlestick injuries.
  • On 4 Nov 2022, Walgreens announces its partnership which expands access to complimentary diabetes. Walgreens aims to contribute to better disease management and improved health outcomes for the diabetes community.

Competitive Landscape

The major global players include Becton, Dickinson and Company, Novo Nordisk A/S, B. Braun Melsungen AG, Owen Mumford, Terumo Corporation, Nipro Corporation, Allison Medical, AdvaCare Pharma, Berpu Medical Technology, Trividia Health.

Why Purchase the Report?

  • To visualize the global pen needles market segmentation based on product, length, therapy, end-user and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of Pen Needles market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global pen needles market report would provide approximately 69 tables, 71 figures and 206 Pages.

Target Audience 2024

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by Lenght
  • 3.3. Snippet by Therapy
  • 3.4. Snippet by End-User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Prevalence of Chronic Diseases
      • 4.1.1.2. Preference for Alternative Modes of Drug Delivery
    • 4.1.2. Restraints
      • 4.1.2.1. Limitations of Pen Needles in Insulin Administration
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.1.2. Market Attractiveness Index, By Product
  • 7.2. Standard Pen Needles *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Safety Pen Needles

8. By Length

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Length
    • 8.1.2. Market Attractiveness Index, By Length
  • 8.2. 4 mm*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. 5 mm
  • 8.4. 6 mm
  • 8.5. 8 mm
  • 8.6. 10 mm
  • 8.7. 12 mm

9. By Therapy

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 9.1.2. Market Attractiveness Index, By Therapy
  • 9.2. Insulin Therapy *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Glucagon-Like Peptide-1
  • 9.4. Growth Hormone Therapy
  • 9.5. Other Therapies

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Diagnostic Centers
  • 10.4. Ambulatory Surgery Centers
  • 10.5. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Length
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Length
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Russia
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Length
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Length
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Length
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Becton, Dickinson and Company*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Novo Nordisk A/S
  • 13.3. B. Braun Melsungen AG
  • 13.4. Owen Mumford
  • 13.5. Terumo Corporation
  • 13.6. Nipro Corporation
  • 13.7. Allison Medical
  • 13.8. AdvaCare Pharma
  • 13.9. Berpu Medical Technology
  • 13.10. Trividia Health

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us